London-based Charm Therapeutics completed an $80 million Series B funding round led by New Enterprise Associates and DR One to develop its next-generation menin inhibitor targeting acute myeloid leukemia (AML). Menin inhibitors disrupt the pathological menin-KMT2A interaction that drives leukemogenesis. Charm’s drug candidate aims to overcome resistance issues seen with existing menin inhibitors, and the capital will support clinical development planned for early 2026. Investors expressed confidence in Charm’s AI-powered platform and preclinical data.